RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of “Moderate Buy” by Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has received a consensus rating of “Moderate Buy” from the twelve ratings firms that are currently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $25.67.

A number of research analysts recently issued reports on RAPT shares. Evercore ISI started coverage on RAPT Therapeutics in a report on Friday, February 16th. They set an “outperform” rating for the company. Wolfe Research assumed coverage on shares of RAPT Therapeutics in a research note on Thursday, February 15th. They set an “outperform” rating and a $39.00 price target for the company. HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a research report on Wednesday, April 10th. JPMorgan Chase & Co. decreased their target price on shares of RAPT Therapeutics from $15.00 to $13.00 and set a “neutral” rating for the company in a research report on Wednesday, March 27th. Finally, Barclays lowered their price target on shares of RAPT Therapeutics from $35.00 to $13.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 21st.

RAPT Therapeutics Stock Performance

NASDAQ RAPT opened at $8.10 on Monday. The stock has a market cap of $281.88 million, a price-to-earnings ratio of -2.66 and a beta of 0.47. The business has a 50 day simple moving average of $8.87 and a 200 day simple moving average of $15.50. RAPT Therapeutics has a 52-week low of $6.86 and a 52-week high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.80) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.05. On average, analysts predict that RAPT Therapeutics will post -3.19 EPS for the current year.

Hedge Funds Weigh In On RAPT Therapeutics

Institutional investors have recently bought and sold shares of the business. TD Asset Management Inc boosted its stake in shares of RAPT Therapeutics by 67.4% during the 3rd quarter. TD Asset Management Inc now owns 153,618 shares of the company’s stock worth $2,553,000 after acquiring an additional 61,831 shares during the period. Hennion & Walsh Asset Management Inc. boosted its position in RAPT Therapeutics by 89.5% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 40,565 shares of the company’s stock worth $674,000 after purchasing an additional 19,161 shares during the period. Swiss National Bank increased its holdings in shares of RAPT Therapeutics by 9.6% in the third quarter. Swiss National Bank now owns 49,100 shares of the company’s stock valued at $816,000 after purchasing an additional 4,300 shares during the last quarter. FMR LLC raised its position in shares of RAPT Therapeutics by 7.4% in the third quarter. FMR LLC now owns 4,499,293 shares of the company’s stock valued at $74,778,000 after purchasing an additional 308,804 shares during the period. Finally, Schonfeld Strategic Advisors LLC raised its position in shares of RAPT Therapeutics by 75.4% in the third quarter. Schonfeld Strategic Advisors LLC now owns 135,045 shares of the company’s stock valued at $2,244,000 after purchasing an additional 58,049 shares during the period. Institutional investors and hedge funds own 99.09% of the company’s stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.